Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Regidor, J. Iñigo, J.M. Sendra, J.L. Gutiérrez-Fisac.
Evolución de la mortalidad por las principales enfermedades crónicas en España, 1975-1988.
Med Clin (Barc, 99 (1992), pp. 725-728
[2.]
A. Viarla, V. Delgado, J. de la Morena.
Morbilidad y mortalidad como indicadores de calidad asistencial en un servicio de medicina interna.
Med Clin (Barc, 96 (1991), pp. 637-638
[3.]
T. León-Colombo, J. Vivasncos-Mora, T. del ser-Quijano, C. Fernández-García, T. Segura-Martín, Dupret C. Monforte, et al.
¿Cómo es el ictus del paciente que ingresamos? Factores de decisión en la hospitalización.
Rev Neurol, 27 (1998), pp. 662-666
[4.]
HP Jr Adams, T.G. Brott, R.M. Crowell, A.J. Furlan, C.R. Gómez, J. Grotta, et al.
Guidelines for the Management of Patients With Acute Ischemic Stroke. A statement for healthcare profesionals from a special writing group of the Stroke Council, American Heart Association.
Stroke, 25 (1994), pp. 1.901-1.914
[5.]
The National Institute of Neurological Disorders rt. -Pa Stroke Study Group. Tissue Plasminogen activator for acute ischernic stroke. Stroke.
N Engl Med, 333 (1995), pp. 1.581-1.587
[6.]
T.G. Kwiatkowski, R.B. Libman, M. Frankel, B.C. Tilley, L.B. Morgenstern, M. Lu, et al.
Effects of Tissue. Plasminogen activator for acute Ischemic. Stroke at one year.
N Engl J Med, 340 (1999), pp. 1.781-1.787
[7.]
W. Hacke, M. Kaste, C. Fieschi, Kummer R. von, A. Davalos, D. Meler, et al.
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravernous alteplase in acute ischaemic stroke (ECASS II.
Lancet, 352 (1998), pp. 1.245-1.251
[8.]
G. Griego, M. d’Hollosy, A.T. Culliford, S. Jonas.
Evaluating neuroprotective, agents for clinical anti-ischemic benefit using neuurological and neuropsychological changes after cardiac surgery under cardiopulmonary byp-ass.
Stroke, 27 (1996), pp. 858-874
[9.]
J.M. Ferro, A.N. Pinto, I. Falcao, G. Rodrígues, J. Ferreira, F. Falcao, et al.
Diagnosis of Stroke by the Nonneurologist: A Validation Study.
Stroke, 29 (1998), pp. 1.106-1.109
[10.]
A. Dávalos, J. Castillo, E. Martínez-Vila.
Delay in Neurological Attention and Stroke Outcome.
Stroke, 26 (1995), pp. 2.233-2.237
[11.]
G. Teasdale, D. Jennett.
Assessment of coma and impaired consciousness. A practical scale.
Lancet, 2 (1974), pp. 81-84
[12.]
R. Cote, R.N. Baltista, C. Wolfson, J. Boucher, J. Adams, V.C. Hachinski.
The Canadian Neurological Scale; validation and reliability assessment.
Neurology, 39 (1989), pp. 638-643
[13.]
F.I. Mahoney, D.W. Barthel.
Functional evaluation: the Barthel index.
Med State Med, 14 (1965), pp. 61-65
[14.]
L.R. Caplan, I. D’Cruz, D.B. Hier.
Atrial size atrial fibrilation and stroke.
Ann Neurol, 19 (1986), pp. 158-161
[15.]
D.E. Singer, E.M. Hylek.
Optimal oral anticoagulant therapy in patients witht nonrheumatic atrial fibrillation and recent cerebral ischemia.
N Engl J Med, 333 (1995), pp. 1.504
[16.]
K.R. Lees.
Does neuroprotecion improve stroke outcome?.
Lancet, 351 (1998), pp. 1.447-1.448
Relación de componentes del grupo: ANEXO 1
Copyright © 2000. Sociedad Española de Medicina Intensiva, Critica y Unidades Coronarias (SEMICYUC) and Elsevier España, S.L.
